Stroke Secondary Prevention: LDL Targets and Inclisiran

Primary Recommendation

The American Heart Association recommends initiating high-intensity statin therapy, targeting LDL-C <70 mg/dL, for stroke secondary prevention; if this target is not achieved, add ezetimibe as second-line therapy, and reserve inclisiran for patients at very high risk who remain above target despite statin plus ezetimibe 1, 2

Target LDL-C <70 mg/dL for all patients with ischemic stroke or TIA attributable to atherosclerotic causes, based on Class I, Level A evidence from the SPARCL trial 1
The TST trial demonstrated superiority of achieving LDL-C <70 mg/dL versus 90-110 mg/dL for preventing major cardiovascular events in stroke survivors, with a strength of evidence classified as Class I, Level B 1
Target LDL-C <55 mg/dL may be considered for patients at very high risk, including those with a history of ischemic stroke plus multiple high-risk conditions, based on Class IIa evidence 2, 4

Initiate atorvastatin 80 mg daily or rosuvastatin 20 mg daily as soon as possible after ischemic stroke or TIA, with a strength of evidence classified as Class I, Level A 1
The SPARCL trial demonstrated that atorvastatin 80 mg reduced stroke recurrence by 16% over 4.9 years, with a hazard ratio of 0.84 and 95% CI 0.71-0.99 1

If LDL-C remains ≥70 mg/dL on maximally tolerated statin, add ezetimibe 10 mg daily, based on Class I, Level B evidence from the TST trial 1, 2, 3
Ezetimibe provides an additional 15-25% LDL-C reduction when added to statin therapy, with a strength of evidence classified as Class I, Level B 1

Inclisiran is reasonable for patients who meet all of the following criteria: very high-risk status, on maximally tolerated statin therapy, already taking ezetimibe, and LDL-C remains >70 mg/dL, based on Class IIa evidence 2

Statins provide a 40% reduction in stroke risk in CKD patients, with similar relative benefit as non-CKD patients, based on evidence from the Kidney International journal 6
PCSK9 inhibitors, including inclisiran, are recommended for CKD patients with ASCVD who achieve <50% LDL-C reduction on high-intensity statins, with a strength of evidence classified as Class IIa 6

Avoid statins after hemorrhagic stroke unless atherosclerotic disease or high cardiovascular risk is present, based on evidence from the Praxis Medical Insights journal 5
The SPARCL trial showed increased hemorrhagic stroke risk with atorvastatin, particularly in patients with prior hemorrhagic stroke, with a hazard ratio of 5.65 and 95% CI 2.82-11.30 5

The recommendation hierarchy is based on Class I, Level A evidence for high-intensity statins, Class I, Level B evidence for ezetimibe, and Class IIa evidence for PCSK9 inhibitors in very high-risk patients 1, 2, 5